Synergy Pharmaceuticals to Present at Canaccord Genuity 36th Annual Growth Conference

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced Marino Garcia, the company’s EVP and Chief Strategy Officer, will present a corporate update at the Canaccord Genuity 36th Annual Growth Conference on Thursday, August 11, 2016 at 10:00 a.m. Eastern Time at the InterContinental in Boston, Massachusetts.

A live webcast of the presentation will be accessible through the Investor Relations section of the company’s website at www.synergypharma.com. A replay of the webcast will be available on Synergy’s website for 60 days following the conference.

About Synergy Pharmaceuticals Inc.

Synergy is a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies. The company has pioneered discovery, research and development efforts around uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Synergy’s proprietary technology platform is based on uroguanylin, a naturally occurring human GI peptide, and includes two lead product candidates – plecanatide and dolcanatide. Plecanatide is the company’s first uroguanylin analog currently being evaluated for use as a once-daily tablet for chronic idiopathic constipation and irritable bowel syndrome with constipation. Dolcanatide is the company’s second uroguanylin analog currently being explored for ulcerative colitis. For more information, please visit www.synergypharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160801005086/en/